Stocks to Watch: Intel, Deckers, Edwards Lifesciences, Genmab

Dow Jones07-24

Intel's second-quarter results well exceeded Wall Street expectations, and the company lifted its 2026 capital expenditures outlook for the year. Shares initially rallied after the bell, at one point gaining more than 10%, and were up 3.5% to $103.75 as of Thursday evening.

Deckers Outdoor's lifted its profit outlook and reported higher first-quarter sales, boosted by growth in its two biggest brands. Still, shares fell 4.8% to $91.65 in after-hours trading.

Edwards Lifesciences reported double-digit revenue growth in the second quarter and lifted the bottom end of its guidance. The stock was up 3.9% to $83.82 after the bell.

A lymphoma drug co-developed by Genmab and AbbVie failed to meet its primary endpoint in a Phase 3 trial. Genmab American Depositary Receipts fell 4% to $28.00.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

July 23, 2026 19:16 ET (23:16 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment